A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

Clin Prostate Cancer. 2005 Sep;4(2):138-41. doi: 10.3816/cgc.2005.n.024.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / drug therapy
  • Benzoquinones
  • Clinical Trials, Phase II as Topic
  • Humans
  • Lactams, Macrocyclic
  • Male
  • Multicenter Studies as Topic
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / drug therapy
  • Protein Serine-Threonine Kinases / antagonists & inhibitors*
  • Research Design
  • Rifabutin / analogs & derivatives*
  • Rifabutin / therapeutic use

Substances

  • Benzoquinones
  • Lactams, Macrocyclic
  • Rifabutin
  • tanespimycin
  • Protein Serine-Threonine Kinases
  • Prostate-Specific Antigen